- Tension: Children with Dravet syndrome have historically faced hundreds of seizures daily with no effective treatment targeting the root cause — now a gene-targeting drug is showing results that seemed impossible.
- Noise: Rare disease breakthroughs often generate premature optimism; the drug is still in early trials and Phase Three testing will determine whether these results hold at scale.
- Direct Message: Zorevunersen isn’t just reducing seizures — it’s offering children with Dravet syndrome something their families never expected to have: a life defined by presence rather than survival.
To learn more about our editorial approach, explore The Direct Message methodology.
Eight-year-old Freddie Truelove used to have hundreds of seizures a day. Now he has a couple a week — and his mother Lauren says the family has “a life we didn’t ever think was possible.” The transformation is the result of a new drug called zorevunersen, and early trial results suggest it could change everything for children with Dravet syndrome, one of the most devastating forms of childhood epilepsy.
Dravet syndrome affects approximately 1 in 15,000 babies born. It’s caused by a mutation in one of two copies of a gene called SCN1A — the gene that tells brain cells how to build sodium channels, the communication infrastructure neurons rely on to send signals. When one copy is faulty, the brain can’t produce enough of those channels. The result is dozens of dangerous seizures daily, beginning in infancy. Children with Dravet often face severe developmental delays, cognitive impairment, and a sharply shortened life expectancy. For families, the diagnosis has historically meant one thing: devastation without an exit door.
Zorevunersen works differently from anything currently available. Rather than suppressing seizures after they start — the approach most anti-epileptic drugs take — this treatment targets the root genetic cause. Administered via spinal infusion, it instructs the brain’s remaining healthy copy of the SCN1A gene to increase production of sodium channels, restoring something closer to normal neural communication. According to the BBC’s reporting on the trial, young patients experienced up to 90% fewer seizures while on repeat doses of the medication.
That number — 90% — deserves a pause. For families who have spent years counting seizures in the hundreds per day, a reduction of that magnitude isn’t an incremental improvement. It’s the difference between a child who can’t leave the house and a child who can go to school.
The trial included 81 participants across the US and UK, with 19 of those patients treated at UK hospitals — Great Ormond Street, Sheffield Children’s Hospital, The Royal Hospital for Children in Glasgow, and University College London. Results demonstrated the treatment can be safely administered to children from age two onwards, a critical finding given that Dravet syndrome typically manifests in the first year of life and causes the most damage during early brain development.
Prof. Helen Cross, one of the lead researchers from University College London’s Institute of Child Health and Great Ormond Street Hospital, called the results both “exciting” and “amazing.” She told the BBC: “With improvements, that gives them real hope that they are able to carry out more normal lives, particularly with their families.”
What strikes me about that quote is the specificity of “particularly with their families.” Dravet syndrome doesn’t just happen to a child. It reshapes every relationship in the household — the constant vigilance, the emergency hospital visits, the siblings who learn early that attention is a finite resource rationed by medical urgency. Families living with severe epilepsy experience recurring losses of the life they expected, triggered every time another child reaches a developmental milestone their child cannot.
Lauren Truelove’s words about her son Freddie capture this with devastating clarity: “We now have a life we didn’t ever think was possible and, most importantly, it’s a life that Freddie can enjoy.” The emphasis on Freddie’s enjoyment — not just survival, not just seizure reduction as a clinical metric — speaks to what these families have been processing for years. The goal was never just fewer seizures. It was personhood. Agency. The ability for a child to experience a day as something other than a medical event.
The science behind zorevunersen represents a broader shift in how medicine approaches genetic neurological conditions. Instead of treating symptoms downstream, researchers are learning to intervene at the source — the gene itself. This mirrors developments we’ve seen in other areas of medicine, including recent breakthroughs in understanding how drugs can alter brain mechanisms rather than simply managing behavioral outputs. The principle is the same: stop chasing effects and start correcting causes.
But zorevunersen is not yet available outside of clinical trials. Galia Wilson, chair of trustees at Dravet Syndrome UK, put it carefully: “We’re now looking forward to the Phase Three clinical trials taking place to see if the early promise we see here will translate into real hope for all those families.” That phrasing — “early promise” translating into “real hope” — reflects the measured caution that rare disease communities learn to adopt. They’ve been burned before by treatments that showed initial results but couldn’t scale, couldn’t get approved, or couldn’t reach the patients who needed them.
And this is where the story gets more complicated. Rare diseases like Dravet syndrome exist in a peculiar space within healthcare systems. With roughly 1 in 15,000 babies affected, the patient population is small enough that pharmaceutical investment has historically been difficult to justify on market terms alone. The families who need these treatments the most are often the ones with the least leverage to demand them. Regulatory pathways for rare disease drugs have improved in recent years — orphan drug designations, accelerated approvals — but the gap between a promising Phase Two result and a drug that’s actually available in a clinic remains vast, expensive, and uncertain.
The emotional architecture of waiting is something these families know intimately. It’s a particular kind of psychological endurance — holding hope loosely enough that it doesn’t destroy you if it falls through, but tightly enough that you keep showing up for trial appointments, keep administering spinal infusions to a toddler, keep believing the data might hold. Rare disease caregiving demands absorbing enormous emotional signals while presenting functional calm to medical teams, school systems, and insurance bureaucracies.
The UK’s involvement in this trial matters for another reason. Nineteen of 81 participants were treated at British hospitals, according to the published findings. That’s roughly a quarter of the trial cohort coming through NHS-affiliated institutions — a meaningful signal that UK research infrastructure can participate in cutting-edge genetic medicine, not just observe it from across the Atlantic. For families in the UK specifically, this means the pathway from trial to clinical availability might be shorter than for treatments developed entirely abroad.
Still, Phase Three trials are where many promising drugs encounter their first real test of durability. Larger patient populations, longer observation periods, placebo controls — the data must hold under scrutiny that Phase Two doesn’t fully impose. The 90% seizure reduction seen in early results is extraordinary, but it’s a figure that will be stress-tested in the months and years ahead. Families like the Trueloves are living inside that uncertainty right now, holding a result that has already transformed their daily life while knowing the broader scientific and regulatory story isn’t finished.
What Freddie Truelove’s story ultimately reveals isn’t just a medical breakthrough. It’s a recalibration of what’s possible — for one child, for one family, and potentially for the roughly 3,500 people living with Dravet syndrome in the UK. Lauren Truelove said the most important thing wasn’t the seizure count. It was that Freddie could enjoy life. That distinction — between surviving and enjoying — is the quiet center of this entire story. Medicine often measures success in reduction: fewer seizures, lower blood pressure, smaller tumors. But the families on the other end of those numbers aren’t counting reductions. They’re watching to see if their child smiles at breakfast. If their child can sit through a story. If their child looks up and, for the first time, seems present in their own life.
That’s what zorevunersen appears to be offering — not a cure, not yet, but something families with Dravet syndrome have almost never been allowed to hold. A future tense. The sentence “my son can now enjoy life” contains an entire world of grief, hope, and stubborn love compressed into eight words. And for the thousands of families still waiting, those words carry a weight that no clinical trial can fully measure — but that every parent immediately understands.
Feature image by Michelle Leman on Pexels
